SRPT has been in the news 321% more than usual
Aug 22, 2025, 8:32 PM
-10.14%
What does SRPT do
Sarepta Therapeutics, based in Cambridge, Massachusetts, focuses on RNA-targeted therapeutics for rare diseases, particularly Duchenne muscular dystrophy, and has developed four approved products. The company employs 1,314 people and has about 40 programs in its pipeline.
SRPT has been in the news recently: Sarepta Therapeutics is facing multiple class action lawsuits for allegedly making misleading statements about its ELEVIDYS therapy between June 22, 2023, and June 24, 2025. The company's stock prices have significantly declined following its announcement to refinance $700 million of convertible notes due in 2027.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.